semaglutide aion The obesity drug (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed. Added Risk of NAION Higher in

A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance use disorders.

GLP-1: Increase in GLUT4 expression by activating AMPK

Keep away from heat

A weekly GLP-1 injection to lose weight, curb hunger, and regulate blood sugar.*

Berberine The breakthrough botanical everyones talking about for metabolism and weight balance

Conclusions Twenty-four weeks of acarbose monotherapy in newly diagnosed patients with T2D is associated with significantly increased levels of both fasting and postprandial GLP-1 as well as significantly increased NO levels and NOS activity for those patients in whom postprandial GLP-1 levels were increased